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Background: LEOPARD syndrome (LS) belongs to the family of neuro-cardio-facio-cutaneous syndromes, which
include Neurofibromatosis-1 (NF1), Noonan syndrome, Costello Syndrome, cardio-facio-cutaneous syndrome,
Noonan-like syndrome with loose anagen hair and Legius syndrome. These conditions are caused by mutations
in genes encoding proteins involved in the RAS-MAPK cellular pathway. Clinical heterogeneity and phenotype
overlaps across those different syndromes is already recognized.
Case presentation: We hereby report a heterozygous de novo mutation in the PTPN11 gene (c.1403C > T)
manifesting with a clinical picture of LS during childhood, and later development of neuropathic pain with
hypertrophic plexi, which are typically observed in NF1 but have not been reported in LS.
Conclusion: LS caused by PTPN11 mutations may be associated with hypertrophic roots and plexi. Consequently,
clinicians should be aware of the possible development of neuropathic pain and consider specific diagnostic
work-up and management.
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LEOPARD syndrome (LS) is defined by Lentigines, Elec-
trocardiographic abnormalities, Ocular hyperthelorism,
Pulmonary valve stenosis, Abnormal genitals, Retarded
growth and Deafness, and is caused by heterozygous muta-
tions in the protein tyrosine phosphatase, non-receptor
type 11 gene (PTPN11). LS is a rare, autosomal dominantly
inherited disease, belonging to the family of neuro-cardio-
facio-cutaneous syndromes (NCFCs). These syndromes
present significant genetic heterogeneity and phenotype
overlaps. Here we describe a patient who arbors a hetero-
zygous mutation in the PTPN11 gene (c.1403C >T) mani-
festing with a clinical phenotype of LS associated with
neuropathic pain and hypertrophic roots and plexi.Case presentation
A Caucasian woman presented with multiple cutaneous
diffuse lentigines and cafe-au-lait spots (7 spots of 0.7 to* Correspondence: alexandre.croquelois@chuv.ch
Department of Clinical Neurosciences, Lausanne University Hospital (CHUV),
Rue du Bugnon 21, 1011 Lausanne, Switzerland
© 2015 Spatola et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.5 cm of diameters, localized in the palms, feet, trunk
and buttock) since the age of 6 years (Figure 1A-D), as-
sociated with mild bilateral ptosis, facial dysmorphism
(such as prognathism necessitating surgery, macroglos-
sia) and pulmonary valve stenosis. Her body weight and
height was in the normal age-range and she had no
psychomotor delay, working as a commercial manager.
Ophthalmologic examination revealed multiple periph-
eral retinal lentigines. Family history was negative for
neurological or cutaneous symptoms.
She was re-examined at the age of 41 years, related to
the development of progressive painful dysaesthesias.
Neurological examination revealed moderate sensory-
motor deficit in all four limbs, with mild facial weakness.
Conventional nerve conduction studies of the upper and
lower limbs were normal, but late spinal F latencies were
diffusely prolonged, suggesting diffuse proximal neur-
opathy. Spinal MRI revealed hypertrophic cervico-
brachial and lumbo-sacral plexi and roots (Figure 1E, F).
Extensive diagnostic work-up excluded other inflamma-
tory, genetic or tumor conditions associated with hyper-
trophic neuropathies [1–3]. MRI of the lower limbs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical and MRI features of LEOPARD syndrome presenting with hypertrophic plexi and neuropathic pain. Patient with LEOPARD
syndrome showing multiple cutaneous lentigines (A and C: trunk, B: palms) and café-au-lait spots, on the upper buttock (D). Spinal MRI showing
hyperthrophy of the cervico-brachial (E) and lumbo-sacral (F) plexi.
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ules (not shown), suggestive of neurofibromas. Sequen-
cing of the NF1 gene showed no mutation (including
search for intragenic rearrangements by MLPA analysis),
while sequencing of the PTPN11 gene revealed a hetero-
zygous missense mutation in Exon 12 (c.1403C > T,
p.Thr468Met), confirming the diagnosis of LS.
Conclusion
We report a patient harboring the PTPN11 c.1403C >T
mutation which manifested with a phenotype of childhood-
onset LS, fulfilling clinical criteria (multiple lentigines plus
2 major features [4]), and later development of neuropathic
pain related to hypertrophic nerve roots and plexi.
The association of skin changes, facial dysmorphism
and mild cardiac abnormalities are almost universally
present in LS patients [4]; sensorineural hearing loss and
neurological deficits (neuropsychological difficulties and
rarely seizures) are present in less than a third of the
cases. Most abnormalities are present at birth, however
some can appear during childhood, as is often the case
for lentigines, or even develop during adulthood, as for
ventricular hypertrophy.
Mutations in PTPN11 are responsible for 80% of LS
cases. The c.1403C > T nucleotide substitution found inour patient is the most frequently reported mutation,
and it leads to a decreased catalytic capacity of the SHP2
protein. RAF1 and BRAF mutations are much less fre-
quently encountered.
LS belongs to the NCFCs family. The most prevalent
disorders of this group are Noonan syndrome and
Neurofibromatosis-1 (NF1), while LS is a rarer condition.
NCFCs display common clinical features such as psycho-
motor delay, facial dysmorphism and cardiac, cutaneous
and skeletal abnormalities. Although genetic causes of
NCFCs are heterogeneous, the molecular mechanisms in-
volved alter the RAS/MAPK signaling pathway [5]. RAS is
a human oncogene implicated in different cellular func-
tions and its transducing signal, involving different MAP
kinases, is critical for cell proliferation and survival. Thus,
its disruption may result in uncontrolled cell growth and
cancer. Somatic mutations in protein components of this
pathway are found in various malignancies [6]. In contrast,
germ-line mutations, which result in a less dysfunctional
gene product, underlie the development of NCFCs.
NCFCs display significant genetic and phenotypic het-
erogeneity: on the one hand, mutations in the same gene
may be responsible for different syndromes, as is the case
for Noonan syndrome and LS, mostly caused by muta-
tions in the PTPN11 gene; on the other hand, dysfunction
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cascade can lead to similar clinical presentations [7,8].
Our patient harbored a PTPN11 de novo mutation man-
ifesting as LS associated with nerve and roots hypertrophy
and neuropathic pain. Although these latter changes, asso-
ciated with gadolinium-enhanced deep nodules evoking
neurofibromas, are typical findings of NF1, our subject
presented no NF1 gene mutations. Recently, three cases
of PTPN11 mutations were reported with early cutaneous,
but no neurological, features of NF1 [9]. Our patient
showed cafe-au-lait spots, however without other derma-
tological hallmarks of NF1, such as skinfold freckling or
cutaneous neurofibromas. Some authors suggested that
NF1 can be misdiagnosed if based solely on the presence
of these skin abnormalities, which can be encountered in
other conditions and disappear with growth [10].
Our observation underscores that LS caused by
PTPN11 mutations could be associated with a proximal
radiculoplexopathy. This finding is of clinical relevance:
while neurologic complications are common in NF1,
they are not routinely screened for in LS patients. Thus,
clinicians should question adult LS individuals about the
development of neuropathic pain and neurological defi-
cits, and perform careful physical examination and con-
sider spinal MRI in search of plexi/root hypertrophy and
neurofibromas.
Neurogenic pain can significantly impact quality of
life, and its management may be challenging. In order to
address different important aspects related to pain, espe-
cially in the context of NCFCs, a multidisciplinary ap-
proach is recommended, associating physical therapy
with medical (including analgesics, opiates, antiepileptic
drugs, topic anesthetics, antidepressants, or a combin-
ation) and psychological treatments [11]. For example, a
multimodal approach including a relaxation response re-
siliency program (3RP) has been recently used in a pilot
study involving patients with NF1, NF2, and schwanno-
matosis, with encouraging results in terms of coping strat-
egies and quality of life [12]. The use of oral ketamine or
bevacizumab has also been suggested as a therapeutic op-
tion in refractory cases of NF1 or NF2, respectively, but its
efficacy only relies on single case reports [13,14]. By con-
trast, surgery should be considered in patients with nerve
or spine compression by plexiform neurofibromas.
Additionally, oncologic screening should be considered
in LS patients presenting deep nodules suggestive of
neurofibromas, particularly in light of the risk for malig-
nant transformation, in analogy to what is observed in
NF1 patients [15]. This is particularly important in the
perspective of promising target-based therapies acting
directly on the RAS/MAPK signaling pathway, such as
MEK and RAF inhibitors [16]. Although it has been sug-
gested that these molecules may play a role in control-
ling tumor progression in various conditions associatedwith neurofibromatosis [16], their effectiveness in neuro-
genic pain control seems to date less prominent [17–19].
Consent
Oral informed consent was obtained from the patient
for publication of this case report and any accompanying
images. Since the patient was not reachable, a written
consent could not be obtained.
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